Study guide
9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management
Key Takeaways Explain This Topic AI
Gestational diabetes mellitus (GDM) is driven by placental secretion of human placental lactogen (hPL), progesterone, growth hormone, and cortisol, which cause marked peripheral insulin resistance that peaks during the late second and early third trimesters.
Diagnostic screening occurs universally at 24 to 28 weeks gestation (or early in high-risk women) via either the Two-Step ACOG method (50-g non-fasting GCT followed by 100-g 3-hr fasting OGTT, requiring >=2 abnormal values) or the One-Step IADPSG method (75-g 2-hr fasting OGTT, requiring >=1 abnormal value).
Strict pregnancy glycemic targets are: fasting blood glucose <95 mg/dL, 1-hour postprandial <140 mg/dL, and 2-hour postprandial <120 mg/dL.
Medical Nutrition Therapy (MNT; 33–40% complex carbohydrates, 20% protein, 40% healthy fats) and physical activity are first-line; insulin is the gold-standard pharmacotherapy when MNT fails to achieve targets within 1 to 2 weeks, as it does not cross the placenta.
Diet-controlled GDM (A1GDM) may undergo expectant management to 40 6/7 weeks, whereas medication-controlled GDM (A2GDM) requires antenatal surveillance starting at 32–36 weeks and delivery between 39 0/7 and 39 6/7 weeks, followed by a 75-g 2-hr OGTT at 4 to 12 weeks postpartum.
Last updated: October 2026
Pathophysiology of Gestational Insulin Resistance
Pregnancy is a naturally diabetogenic state characterized by progressive, physiological insulin resistance. This adaptation ensures that maternal glucose is preferentially shunted across the placenta via facilitated diffusion (GLUT-1 transporters) to sustain rapid embryonic and fetal development.
Placental Diabetogenic Hormones
Beginning around 20 to 24 weeks gestation and peaking in the third trimester, the syncytiotrophoblast secretes an array of counter-regulatory hormones:
Human Placental Lactogen (hPL / Human Chorionic Somatomammotropin): The primary mediator of maternal insulin resistance. hPL stimulates lipolysis, releasing maternal free fatty acids for maternal energy while impairing post-receptor insulin signaling in maternal skeletal muscle and adipose tissue.
Progesterone & Estrogen: Inhibit glucose uptake in peripheral tissues and downregulate insulin receptor substrate-1 (IRS-1).
Placental Growth Hormone (PGH): Modifies maternal hepatic gluconeogenesis and somatomedin generation.
Cortisol & Prolactin: Elevated maternal free cortisol further promotes gluconeogenesis and blunts peripheral insulin sensitivity.
Tumor Necrosis Factor-alpha (TNF-α): Placental cytokine that strongly impairs insulin receptor autophosphorylation.
In healthy pregnancies, maternal pancreatic beta cells undergo compensatory hyperplasia and hypertrophy, increasing insulin secretion by 200% to 250% to maintain maternal euglycemia. Gestational diabetes mellitus (GDM) develops when pancreatic reserve is inadequate to overcome this physiological peripheral insulin resistance.
- Screening & Diagnostic Paradigms: Two-Step vs. One-Step
- Screening Strategy & Timing
Universal Screening: Conducted between 24 0/7 and 28 6/7 weeks gestation for all pregnant women not previously identified with diabetes.
Early Screening: Conducted at the initial prenatal visit in women with major risk factors: pre-pregnancy BMI ≥25 kg/m² (≥23 kg/m² in Asian Americans) plus high-risk markers (prior GDM, HbA1c ≥5.7%, polycystic ovary syndrome, first-degree relative with type 2 diabetes, or prior macrosomic infant ≥4,000 g). If early testing is negative, repeat screening at 24 to 28 weeks remains mandatory.
The Two-Step Approach (ACOG & Carpenter-Coustan Criteria)
Standard in the United States:
Step 1: 50-g Glucose Challenge Test (GCT): Non-fasting screening test. A 50-gram oral glucose load is consumed, and venous plasma glucose is measured 1 hour later.
Threshold: A plasma glucose of ≥130 or ≥140 mg/dL (institutional standard) is considered abnormal and mandates proceeding to Step 2.
Direct Diagnosis: If the initial 50-g screen is ≥200 mg/dL , GDM is diagnosed directly without requiring the 3-hour test.
Step 2: 100-g 3-Hour Oral Glucose Tolerance Test (OGTT): Performed in the morning after an overnight fast of 8 to 14 hours following at least 3 days of unrestricted carbohydrate intake (>150 g/day).
- Measurement Time Carpenter-Coustan Threshold (mg/dL) NDDG Threshold (mg/dL)
- Fasting ≥95 ≥105
- 1-Hour ≥180 ≥190
- 2-Hour ≥155 ≥165
- 3-Hour ≥140 ≥145
Note
Under the Carpenter-Coustan criteria, at least two of the four plasma glucose values must meet or exceed the threshold to confirm a diagnosis of GDM. If only one value is elevated, the patient is at increased risk for macrosomia and is often monitored or re-evaluated at 32 weeks.
The One-Step Approach (IADPSG / ADA Criteria)
Endorsed internationally by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and World Health Organization (WHO):
Patient undergoes a 75-g 2-hour fasting OGTT at 24 to 28 weeks.
Diagnostic thresholds: Fasting ≥92 mg/dL , 1-hour ≥180 mg/dL , 2-hour ≥153 mg/dL .
Diagnosis is confirmed if any single value meets or exceeds these cutoffs.
- Glycemic Targets & Medical Nutrition Therapy
- Glycemic Targets in Pregnancy
Maintaining strict maternal euglycemia prevents fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia, and shoulder dystocia:
Fasting Blood Glucose: <95 mg/dL (5.3 mmol/L).
1-Hour Postprandial: <140 mg/dL (7.8 mmol/L).
2-Hour Postprandial: <120 mg/dL (6.7 mmol/L).
Hemoglobin A1c: Target in pregnancy is <6.0% (42 mmol/mol), provided it can be achieved without significant maternal hypoglycemia. A1c turnover is accelerated in pregnancy due to increased red cell production.
Medical Nutrition Therapy (MNT)
First-line therapy for all patients diagnosed with GDM (A1GDM). An individualized nutritional plan developed with a registered dietitian:
Caloric Intake: 30 kcal/kg/day for normal-weight women; 22 to 25 kcal/kg/day for overweight/obese women (avoiding caloric restriction <1,600–1,800 kcal/day to prevent starvation ketosis).
Macronutrient Distribution:
Complex Carbohydrates: 33% to 40% of total daily calories, distributed across meals. Emphasize low glycemic index foods rich in fiber.
Protein: 20% of daily calories.
Fat: 40% of daily calories, emphasizing monounsaturated and polyunsaturated fats.
Meal Patterning: Three small-to-moderate meals and 2 to 3 snacks daily . A bedtime snack containing complex carbohydrates and protein is mandatory to prevent nocturnal hepatic glycogen depletion, overnight hypoglycemia, and morning rebound ketonemia.
Physical Activity: Moderate aerobic exercise for 30 minutes, 5 days per week, or 10 to 15 minutes of brisk walking following each meal blunts postprandial glucose excursions.
- Pharmacotherapy, Fetal Surveillance & Delivery
- Pharmacologic Management
When MNT and exercise fail to achieve target blood glucose levels within 1 to 2 weeks , pharmacologic therapy is indicated (A2GDM).
Insulin (First-Line Gold Standard): Does not cross the placenta and achieves predictable glycemic control without fetal exposure.
Regimens: Split-dose basal-bolus therapy utilizing intermediate-acting NPH insulin (basal) and rapid-acting analogs insulin lispro or aspart (bolus before meals). Rapid-acting analogs exhibit minimal transplacental transfer and have favorable safety profiles.
Starting Dose: Total daily dose calculated at 0.7 to 1.0 unit/kg actual pregnancy weight, titrated according to patient logs.
Oral Antihyperglycemic Agents (Second-Line / Limitations):
Metformin: Crosses the placenta readily, producing umbilical cord concentrations equal to or higher than maternal blood. While not teratogenic, it has high failure rates (up to 30–50% require supplemental insulin) and may alter long-term offspring metabolic programming. Reserved for patients who refuse or cannot afford/administer insulin.
Glyburide: Crosses the placenta and is associated with significantly higher rates of neonatal hypoglycemia and macrosomia compared to insulin. It is not recommended as first-line therapy.
Important
Insulin remains the only first-line pharmacotherapy recommended by ACOG and the ADA for gestational diabetes because oral agents cross the placenta and lack reassuring long-term offspring outcome data.
Antenatal Fetal Surveillance & Delivery Timing
Diet-Controlled GDM (A1GDM): Fetal surveillance (NST/BPP) is generally not required before 40 weeks unless comorbidities arise. Expectant management is permitted up to 40 6/7 weeks gestation .
Medication-Controlled GDM (A2GDM): Initiate weekly or twice-weekly antenatal surveillance (non-stress testing [NST] and/or biophysical profile [BPP]) starting at 32 to 36 weeks gestation . Scheduled delivery is recommended between 39 0/7 and 39 6/7 weeks gestation .
Macrosomia & Cesarean Consideration: If ultrasound estimated fetal weight (EFW) exceeds 4,500 grams , clinicians should counsel patients regarding the option of scheduled cesarean delivery to avoid traumatic shoulder dystocia and brachial plexus injury.
Postpartum Metabolic Re-evaluation
Because placental expulsion removes the source of anti-insulin hormones, insulin resistance drops precipitously immediately postpartum. Discontinue all insulin and oral agents following delivery.
Screening Interval: Perform a 75-g 2-hour fasting OGTT at 4 to 12 weeks postpartum to screen for persistent diabetes or prediabetes.
Interpretation (Non-pregnant criteria): Fasting <100 mg/dL and 2-hr <140 mg/dL is normal; fasting 100–125 mg/dL indicates impaired fasting glucose; 2-hr 140–199 mg/dL indicates impaired glucose tolerance; fasting ≥126 mg/dL or 2-hr ≥200 mg/dL confirms type 2 diabetes mellitus.
Long-Term Risk: Women with prior GDM have a 50% to 70% lifetime risk of developing overt type 2 diabetes and require re-screening every 1 to 3 years.